Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 35
Filter
1.
Acta Diabetol ; 52(2): 239-47, 2015 Apr.
Article in English | MEDLINE | ID: mdl-25109286

ABSTRACT

The risk-to-benefit ratio for the use of low dose of aspirin in primary cardiovascular (CV) prevention in patients with diabetes mellitus remains to be clarified. We assessed the effect of aspirin on risk of CV events in type 2 diabetic patients with nephropathy, in order to verify the usefulness of Guidelines in clinical practice. We carried out a prospective multicentric study in 564 patients with type 2 diabetic nephropathy free of CV disease attending outpatient diabetes clinics . A total of 242 patients received antiplatelet treatment with aspirin 100 mg/day (group A), and 322 were not treated with antiplatelet drugs (group B). Primary end point was the occurrence of total major adverse cardio-vascular events (MACE). Secondary end points were the relative occurrence of fatal MACE. The average follow-up was 8 years. Total MACE occurred in 49 patients from group A and in 52 patients from group B. Fatal MACE occurred in 22 patients from group A and in 20 from group B; nonfatal MACE occurred in 27 patients from group A and in 32 patients from group B. Kaplan-Meier analysis did not show a statistically significant difference of cumulative MACE between the two groups. A not statistically significant difference in the incidence of both fatal (p = 0.225) and nonfatal CV events (p = 0.573) between the two groups was observed. These results were confirmed after adjustment for confounders (HR for MACE 1.11, 95 % CI 0.91-1.35). These findings suggest that low dose of aspirin is ineffective in primary prevention for patients with nephropathy.


Subject(s)
Aspirin/administration & dosage , Cardiovascular Diseases/prevention & control , Diabetes Mellitus, Type 2/complications , Diabetic Nephropathies/complications , Aged , Cardiovascular Diseases/etiology , Drug Evaluation , Female , Follow-Up Studies , Humans , Male , Middle Aged , Platelet Aggregation Inhibitors/administration & dosage , Primary Prevention , Prospective Studies , Risk Assessment
2.
J Am Heart Assoc ; 3(2): e000434, 2014 Mar 26.
Article in English | MEDLINE | ID: mdl-24670789

ABSTRACT

BACKGROUND: Diabetes mellitus (DM) has multifactorial detrimental effects on myocardial tissue. Recently, carbonic anhydrases (CAs) have been shown to play a major role in diabetic microangiopathy but their role in the diabetic cardiomyopathy is still unknown. METHODS AND RESULTS: We obtained left ventricular samples from patients with DM type 2 (DM-T2) and nondiabetic (NDM) patients with postinfarct heart failure who were undergoing surgical coronary revascularization. Myocardial levels of CA-I and CA-II were 6- and 11-fold higher, respectively, in DM-T2 versus NDM patients. Elevated CA-I expression was mainly localized in the cardiac interstitium and endothelial cells. CA-I induced by high glucose levels hampers endothelial cell permeability and determines endothelial cell apoptosis in vitro. Accordingly, capillary density was significantly lower in the DM-T2 myocardial samples (mean±SE=2152±146 versus 4545±211/mm(2)). On the other hand, CA-II was mainly upregulated in cardiomyocytes. The latter was associated with sodium-hydrogen exchanger-1 hyperphosphorylation, exaggerated myocyte hypertrophy (cross-sectional area 565±34 versus 412±27 µm(2)), and apoptotic death (830±54 versus 470±34 per 10(6) myocytes) in DM-T2 versus NDM patients. CA-II is activated by high glucose levels and directly induces cardiomyocyte hypertrophy and death in vitro, which are prevented by sodium-hydrogen exchanger-1 inhibition. CA-II was shown to be a direct target for repression by microRNA-23b, which was downregulated in myocardial samples from DM-T2 patients. MicroRNA-23b is regulated by p38 mitogen-activated protein kinase, and it modulates high-glucose CA-II-dependent effects on cardiomyocyte survival in vitro. CONCLUSIONS: Myocardial CA activation is significantly elevated in human diabetic ischemic cardiomyopathy. These data may open new avenues for targeted treatment of diabetic heart failure.


Subject(s)
Carbonic Anhydrase II/metabolism , Carbonic Anhydrase I/metabolism , Diabetes Mellitus, Type 2/complications , Diabetic Cardiomyopathies/enzymology , Endothelial Cells/enzymology , Myocardial Ischemia/enzymology , Myocytes, Cardiac/enzymology , Ventricular Remodeling , Aged , Animals , Apoptosis , Blood Glucose/metabolism , Carbonic Anhydrase I/genetics , Carbonic Anhydrase II/genetics , Cardiomegaly/enzymology , Cardiomegaly/pathology , Cation Transport Proteins/metabolism , Cells, Cultured , Diabetic Cardiomyopathies/pathology , Diabetic Cardiomyopathies/physiopathology , Endothelial Cells/pathology , Enzyme Activation , Female , Humans , Male , MicroRNAs/metabolism , Middle Aged , Myocardial Ischemia/pathology , Myocardial Ischemia/physiopathology , Myocytes, Cardiac/pathology , Phosphorylation , Rats , Rats, Wistar , Signal Transduction , Sodium-Hydrogen Exchanger 1 , Sodium-Hydrogen Exchangers/metabolism , Up-Regulation , p38 Mitogen-Activated Protein Kinases/metabolism
3.
Recenti Prog Med ; 104(2): 49-53, 2013 Feb.
Article in Italian | MEDLINE | ID: mdl-23535956

ABSTRACT

The risk of loss of essential elements of our professionalism, such as sense of duty, altruism and collegiality, contributes to the difficulties in the interplay between health services administration, health professionals and patients. It is not enough to increase salaries or change organization models. It is also insufficient a generic reference to the values of our profession, but it is mandatory to overcome the self-referencing attitude of health professions.


Subject(s)
Health Personnel/psychology , Health Services Administration , Interprofessional Relations , Patients/psychology , Professional-Patient Relations , Altruism , Attitude of Health Personnel , Authoritarianism , Health Facility Administrators/psychology , Health Occupations , Humans , Organizational Culture , Personal Autonomy , Personal Satisfaction , Professional Practice/trends , Self Concept
4.
Diab Vasc Dis Res ; 9(1): 10-7, 2012 Jan.
Article in English | MEDLINE | ID: mdl-22064696

ABSTRACT

OBJECTIVE: Non-invasive testing often does not identify coronary artery disease (CAD) in diabetic subjects. This study was designed in order to examine the prevalence of CAD in a cohort of asymptomatic type 2 diabetic patients at high cardiovascular risk and negative nuclear imaging, using multi-slice computed tomography (MSCT) angiography. METHODS: In total, 770 type 2 diabetic patients were screened from January 2008 through July 2010. Of these, 132 Caucasians with diabetic nephropathy and asymptomatic for angina were eligible for a cross-sectional study. Patients underwent MSCT after ischaemia was excluded by myocardial Single Photon Emission Computed Tomography (SPECT) at rest and after dynamic exercise. When obstructive plaques were found (≥ 50% lumen narrowing), patients were sent to conventional coronary angiography (CCA). RESULTS: Six subjects were not included in the analysis because of motion artefacts. MSCT was positive for CAD in 114 patients (90%). Within patients with positive MSCT, 60 (48% of all) showed one or more obstructive plaques. CCA confirmed significant stenosis (≥ 50%) in 48 of these 60 patients (80%). Some 21 (35%) showed stenosis ≥ 75% and were submitted to the revascularisation procedure. CONCLUSION: MSCT seems to better identify CAD than myocardial SPECT in asymptomatic patients with type 2 diabetes and diabetic nephropathy.


Subject(s)
Coronary Angiography/methods , Coronary Stenosis/diagnostic imaging , Diabetes Mellitus, Type 2/epidemiology , Diabetic Nephropathies/epidemiology , Tomography, X-Ray Computed , Aged , Asymptomatic Diseases , Chi-Square Distribution , Coronary Stenosis/epidemiology , Coronary Stenosis/therapy , Cross-Sectional Studies , Female , Humans , Italy/epidemiology , Logistic Models , Male , Middle Aged , Myocardial Revascularization , Predictive Value of Tests , Prevalence , Risk Assessment , Risk Factors , Severity of Illness Index , Tomography, Emission-Computed, Single-Photon
5.
Nephrol Dial Transplant ; 27(6): 2269-74, 2012 Jun.
Article in English | MEDLINE | ID: mdl-22090446

ABSTRACT

BACKGROUND: In Type 2 diabetic patients, clinical diagnosis of diabetic nephropathy (DN) is generally based on the concomitant presence of abnormal albuminuria and severe retinopathy. In this high-risk population, cardiovascular (CV) outcome has never been evaluated. METHODS: A cohort of 742 Type 2 diabetic patients with DN from 17 national centres was selected by the presence of persistent albuminuria ≥ 30 mg/day and severe diabetic retinopathy and was followed prospectively. Time to CV event (CV death, non-fatal myocardial infarction, non-fatal stroke, revascularization, major amputation) was the primary composite end point and it was analysed by multivariable Cox's proportional hazards model. The interaction between albuminuria and glomerular filtration rate (GFR) was specifically investigated. RESULTS: Median follow-up was 4.6 years. Overall 242 events (26% of which fatal) were observed in 202 patients. The proportion of CV events increased from 19 to 40% as GFR declined from the highest (≥ 90 mL/min/1.73 m(2)) to the lowest (<45 mL/min/1.73 m(2)) category and was equal to 25 and 33% in microalbuminuria and macroalbuminuria, respectively. In multivariable analysis, the interaction between albuminuria and GFR was statistically significant (P = 0.012). Albuminuria, indeed, had a remarkable prognostic effect in subjects with high GFR that virtually disappeared as GFR became <30 mL/min/1.73 m(2). Age, smoking habit, previous occurrence of myocardial infarction or stroke and proliferative retinopathy were all found to have a statistically significant prognostic effect on CV outcome. CONCLUSIONS: A clinically based diagnosis of DN in Type 2 diabetes allows the identification of subjects with high CV risk. Albuminuria has a relevant prognostic effect on CV morbidity and mortality; its effect is especially pronounced when GFR is normal or near normal.


Subject(s)
Albuminuria/diagnosis , Cardiovascular Diseases/etiology , Diabetes Complications/etiology , Diabetes Mellitus, Type 2/physiopathology , Diabetic Nephropathies/complications , Diabetic Nephropathies/etiology , Glomerular Filtration Rate , Aged , Albuminuria/etiology , Blood Pressure , Creatinine/blood , Cross-Sectional Studies , Female , Follow-Up Studies , Humans , Male , Middle Aged , Prognosis , Prospective Studies , Risk Factors
6.
Curr Drug Metab ; 12(7): 658-66, 2011 Sep.
Article in English | MEDLINE | ID: mdl-21495978

ABSTRACT

Despite the growing of pharmacological options for the treatment of diabetes, epidemiological studies suggest that a substantial proportion of patients does not achieve glycemic goals and so suffers from the risk of chronic complications. This review explores the inhibition of renal glucose reabsorption as a novel approach to treat hyperglycemia. Sodium-glucose cotransporter 2 (SGLT2), a low-affinity high-capacity transporter located in the brush-border membrane of the early segment (S1) of the proximal renal tubule, accounts for about 90% of the reabsorption of glucose from tubular fluid. Competitive inhibitors of SGLT2 that are responsible for renal excretion of glucose provide a unique mechanism to potentially lower the elevated blood glucose levels in patients with diabetes. They act independently of insulin secretion, thereby minimizing the risk of hypoglycemia and weight gain, to control energy balance in a negative direction, a distinctive advantage of this class of drugs over existing oral hypoglycemic agents. Although this group of medications is still under investigation, it appears to be safe and generally well tolerated and it would be expected to improve the treatment of type 2 diabetes as monotherapy or in combination with other oral or parenteral agents. Dapagliflozin is the first agent within this class, which induces clinically meaningful reductions in FPG, PPG, HbA1c, and body weight in type 2 diabetes.


Subject(s)
Diabetes Mellitus, Type 2/metabolism , Drug Delivery Systems/trends , Hypoglycemic Agents/administration & dosage , Kidney/metabolism , Kidney/pathology , Sodium-Glucose Transporter 2/metabolism , Animals , Blood Glucose/drug effects , Blood Glucose/metabolism , Diabetes Mellitus, Type 2/drug therapy , Diabetes Mellitus, Type 2/pathology , Drug Delivery Systems/methods , Humans , Kidney/drug effects , Sodium-Glucose Transporter 2 Inhibitors
8.
J Clin Endocrinol Metab ; 95(1): 194-200, 2010 Jan.
Article in English | MEDLINE | ID: mdl-19892836

ABSTRACT

CONTEXT: Food intake induces relevant cardiovascular changes together with parallel increases in cardiac sympathetic activity and insulin plasma levels in man. OBJECTIVE: We evaluated hemodynamics, neurohormones, and cardiac autonomic control after eating in patients with type 1 diabetes, a disease characterized by the absence of basal and stimulated insulin production. DESIGN AND SETTING: Fifteen type 1 diabetic patients and 15 healthy controls underwent blood sampling, electrocardiogram, blood pressure and respiration recordings, and heart rate variability analysis while recumbent, during the 70 degrees head-up tilt, and 20 min after a mixed meal; on another occasion, diabetic patients were also studied 20 min after a mixed meal preceded by their scheduled bolus of exogenous insulin. Spectrum analysis of RR interval provided the indices of sympathetic (LF(RR)) and vagal (HF(RR)) modulation of the sinoatrial node. RESULTS: At baseline, no significant differences were found between groups, except for metabolic parameters. Compared with baseline, heart rate, plasma catecholamines, and LF(RR) significantly (P < 0.005) increased, whereas HF(RR) significantly (P < 0.0001) decreased during the tilt in all subjects. Compared with baseline, plasma norepinephrine, heart rate, and LF(RR) significantly (P < 0.05) increased, whereas HF(RR) significantly (P < 0.02) decreased after eating in controls but not in diabetic patients (with and without insulin administered before eating). In both controls and diabetic patients, no relationship between postprandial changes of insulin and LF(RR) and HF(RR) was found. CONCLUSIONS: Hemodynamic, neurohormonal, and cardiac neural responses to eating are abnormal in type 1 diabetic patients, independently of insulin.


Subject(s)
Autonomic Nervous System/physiology , Diabetes Mellitus, Type 1/physiopathology , Eating/physiology , Heart/physiology , Hemodynamics/physiology , Adult , Blood Glucose/analysis , Blood Pressure/physiology , Drug Administration Schedule , Female , Heart/innervation , Heart Rate/physiology , Humans , Insulin/administration & dosage , Male , Posture/physiology , Tilt-Table Test , Young Adult
9.
Clin Chem Lab Med ; 47(10): 1217-25, 2009.
Article in English | MEDLINE | ID: mdl-19803812

ABSTRACT

BACKGROUND: The poor response to antiviral treatment of hepatitis C virus (HCV)-infected patients with genotype 1b has been associated with a higher prevalence of metabolic syndrome. However, the molecular link between these clinical entities is not clear. The goal of this study was to clarify the role of genotype 1b and 2 in the genetic expression of suppressor of cytokine signaling 3 (SOCS3) and insulin receptor substrate 1 (IRS-1). METHODS: We infected human hepatocellular carcinoma cell line (HepG2) cells with human HCV genotype 1b or 2 and measured the gene and protein expression of SOCS3 at various times. We also evaluated impairment in the insulin pathway by analysis of IRS-1 and phospho-AKT. For the control, we used HepG2 cell cultures treated with non-infectious serum. We also demonstrated the occurrence of HCV infection by the detection of both positive and negative strands in the cells and culture medium. To test infection of the HepG2 cells, we performed quantitative real-time polymerase chain reaction (qRT-PCR) of viral load at different time points. We analyzed the viral genotype in the pellet and supernatant. RESULTS: At each time point, we found positive and negative strands in the infected cells, while in the medium we found positive, but no negative strands. We also detected the presence of the correct genotype in the medium. Two weeks following infection when the viral load was higher, we tested genotype 1b and 2 infected cells. SOCS3 gene expression was significantly higher in genotype 1b-infected cells (median 2.56; mean 2.82+/-0.59) compared with genotype 2 (median 1.34; mean 1.46+/-0.31) (p=0.04) and control cells (median 1.09; mean 1.02+/-0.11, p=0.02). There was no difference between cells exposed to genotype 2 and control cells. Conversely, IRS-1 was significantly lower in genotype 1b-infected cells (median 15.97; mean 15.45+/-0.67) compared with genotype 2-infected cells (median 16.45; mean 16.44+/-0.01, p=0.04). Statistically significant differences were seen when comparing the pAKT/AKT ratio in genotype 1b-infected cells (0.19+/-0.034) and not genotype 1b-infected (genotype 2-infected and non-infected) cells (0.253+/-0.004, p=0.03). This inverse regulation is compatible with interactions between the molecular expression of SOCS3, IRS-1 and phospho-AKT mediated by the genotype 1b virus. CONCLUSIONS: Up-regulation of the SOCS3 gene might be one of the mechanisms governing non-response to therapy and expression of insulin resistance mediated via a direct mechanism at this level of genotype 1b HCV.


Subject(s)
Gene Expression Regulation , Hepacivirus/physiology , Hepatitis C/genetics , Insulin Receptor Substrate Proteins/genetics , Insulin Receptor Substrate Proteins/metabolism , Suppressor of Cytokine Signaling Proteins/genetics , Suppressor of Cytokine Signaling Proteins/metabolism , Genotype , Hep G2 Cells , Hepatitis C/metabolism , Humans , Proto-Oncogene Proteins c-akt/metabolism , Suppressor of Cytokine Signaling 3 Protein , Virus Replication
10.
Curr Diabetes Rev ; 5(2): 92-101, 2009 May.
Article in English | MEDLINE | ID: mdl-19442094

ABSTRACT

Glucagon-like peptide-1 (GLP-1) is a gut hormone that plays an important role in regulating glucose homeostasis by both its pancreatic and extrapancreatic activity. Defects of GLP-1 characterize type 2 diabetes as a primary or perhaps consequent phenomenon, resulting in inappropriately low insulin secretion after oral ingestion of nutrients. The discovery that cleavage by the ubiquitous enzyme dipeptidyl peptidase-IV (DPP-IV) is the primary route of GLP-1 metabolism formed the rationale behind the proposal to prevent degradation of endogenously released GLP-1 by DPP-IV inhibition as a novel approach to the management of type 2 diabetes. Enhanced insulin secretion as well as delayed gastric emptying, reduced glucagon secretion, and inhibited apoptosis of beta cells resulting from blockade of incretin degradation, have been proposed as the major actions of DPP-IV inhibitors as antidiabetic agents. Clinical studies to date indicate that DPP-IV inhibitors effectively ameliorate islet dysfunction and improve glucose control in patients with type 2 diabetes. They appear to have excellent therapeutic effectiveness as monotherapy in patients inadequately controlled with diet and exercise and as add-on therapy in combination with metformin, thiazolidinediones, and insulin. Their pharmacokinetic and pharmacodynamic profiles support once-daily dosing, with relatively few adverse effects.


Subject(s)
Diabetes Mellitus, Type 2/drug therapy , Dipeptidyl-Peptidase IV Inhibitors/administration & dosage , Glucagon-Like Peptide 1/metabolism , Glucose/metabolism , Administration, Oral , Clinical Trials as Topic , Diabetes Mellitus, Type 2/enzymology , Humans , Incretins/metabolism
11.
World J Gastroenterol ; 15(4): 462-6, 2009 Jan 28.
Article in English | MEDLINE | ID: mdl-19152451

ABSTRACT

AIM: To investigate the prevalence of the clinical parameters of insulin resistance and diabetes in patients affected by chronic hepatitis C (CHC) or chronic hepatitis B (CHB). METHODS: We retrospectively evaluated 852 consecutive patients (726 CHC and 126 CHB) who had undergone liver biopsy. We recorded age, sex, ALT, type 2 diabetes and/or metabolic syndrome (MS), body mass index (BMI), and apparent disease duration (ADD). RESULTS: Age, ADD, BMI, prevalence of MS and diabetes in patients with mild/moderate liver fibrosis were significantly higher in CHC. However, the degree of steatosis and liver fibrosis evaluated in liver biopsies did not differ between CHC and CHB patients. At multivariate analysis, age, sex, BMI, ALT and diabetes were independent risk factors for liver fibrosis in CHC, whereas only age was related to liver fibrosis in CHB. We also evaluated the association between significant steatosis (>30%) and age, sex, BMI, diabetes, MS and liver fibrosis. Diabetes, BMI and liver fibrosis were associated with steatosis >30% in CHC, whereas only age and BMI were related to steatosis in CHB. CONCLUSION: These data may indicate that hepatitis C virus infection is a risk factor for insulin resistance.


Subject(s)
Hepatitis B, Chronic/metabolism , Hepatitis C, Chronic/metabolism , Insulin Resistance , Adult , Aged , Cohort Studies , Diabetes Mellitus, Type 2/complications , Female , Hepatitis B, Chronic/complications , Hepatitis C, Chronic/complications , Humans , Male , Metabolic Syndrome/complications , Middle Aged , Retrospective Studies , Risk Factors
12.
Am J Gastroenterol ; 103(12): 3159-66, 2008 Dec.
Article in English | MEDLINE | ID: mdl-18786125

ABSTRACT

BACKGROUND AND AIMS: A deranged metabolic status and alcohol intake may trigger induction and progression of chronic hepatitis C virus (HCV) liver disease. The aim of this study was to evaluate whether dietary composition affects the severity of liver damage and response to therapy in patients with HCV-related chronic hepatitis. METHODS: We enrolled 1,084 patients with biopsy-proven HCV-related chronic hepatitis (432 treated with interferon plus ribavirin) and 2,326 healthy subjects in this prospective study conducted in a university hospital. Dietary habits were recorded in enrolled individuals, and their alcohol consumption was evaluated with a questionnaire (AUDIT). Body mass index, and plasma levels of blood glucose, nitrogen, creatinine, cholesterol, and triglycerides were also measured. All individuals underwent routine liver tests and HCV genotyping. RESULTS: At study onset, there were no differences in metabolic status or alcohol consumption between patients and controls. About 50% of each group was overweight, and about 60% consumed alcohol. Patients and controls had similar dietary habits. Intake of carbohydrates, lipids and polyunsaturated fatty acids, and alcohol consumption were independent factors of liver damage at histology (logistic regression analysis). Some dietary components (unsaturated fatty acids, iron, zinc, vitamin A, and niacin) and alcohol intake differed significantly (P < 0.05 and P 0.01, respectively; univariate analysis) between responders and nonresponders to interferon therapy. Genotype, age, body mass index, steatosis, and fibrosis were independent predictors of therapy outcome (P < 0.02; multivariate analysis). CONCLUSIONS: The severity of HCV-related chronic hepatitis depends on a variety of factors. Our results show that dietary composition is related to the extent of liver damage. Although traditional risk factors independently affected treatment response, some dietary components were associated with nonresponse to therapy in our patients. This suggests that HCV patients may benefit from instructions regarding their diet.


Subject(s)
Antiviral Agents/therapeutic use , Diet , Hepatitis C, Chronic/complications , Interferons/therapeutic use , Liver Cirrhosis/drug therapy , Adult , Aged , Aged, 80 and over , Alcohol Drinking/adverse effects , Female , Humans , Liver Cirrhosis/etiology , Male , Middle Aged , Prospective Studies , Ribavirin/therapeutic use , Young Adult
13.
J Hepatol ; 49(4): 557-63, 2008 Oct.
Article in English | MEDLINE | ID: mdl-18678434

ABSTRACT

BACKGROUND/AIMS: Prevalence of HCV infection in non-Hodgkin's lymphoma is high. The impact of antiviral therapy on the natural history of this subgroup of lymphomas after a successful chemotherapy regimen is still an argument of debate. METHODS: We retrospectively examined 343 chemotherapy-treated patients referred to our centre for five consecutive years. Clinical and histological characteristics, disease free-survival (DFS) and overall-survival (OS) were compared in HCV-positive (69/343) and HCV-negative (274/343) patients. Twenty-five HCV-positive patients received antiviral treatment following chemotherapy discontinuation. Uni- and multivariate analyses were performed. RESULTS: 20% of lymphomas were HCV-positive. Indolent histology was prevalent in the HCV-positive group (p<0.05); no significant differences in OS or DFS were found between the two groups; in HCV-positive subjects, antiviral therapy, was associated with a longer DFS (p<0.05); none of the HCV-positive subjects who achieved a virological response experienced any lymphoma relapse; 29% of non responders did; at multivariate analysis, the independent factors related to a better clinical outcome were: indolent histology at the onset of lymphoma and antiviral therapy. CONCLUSIONS: Antiviral treatment in HCV-positive non-Hodgkin's lymphoma may be an important strategy to reinforce the results of a successful chemotherapy regimen; further studies are needed to validate this combined approach.


Subject(s)
Antineoplastic Agents/therapeutic use , Antiviral Agents/therapeutic use , Hepatitis C/drug therapy , Lymphoma, Non-Hodgkin/drug therapy , Lymphoma, Non-Hodgkin/virology , Adolescent , Adult , Aged , Aged, 80 and over , Cohort Studies , Female , Hepacivirus/pathogenicity , Humans , Interferons/therapeutic use , Kaplan-Meier Estimate , Liver/pathology , Liver/virology , Male , Middle Aged , Multivariate Analysis , Retrospective Studies , Ribavirin/therapeutic use , Treatment Outcome , Young Adult
14.
Hepatology ; 46(4): 1009-15, 2007 Oct.
Article in English | MEDLINE | ID: mdl-17668875

ABSTRACT

UNLABELLED: The response to antiviral therapy is lower in hepatitis C virus (HCV) patients with genotype 1 than in those with genotype 2. Overexpression of the suppressor of cytokine signaling 3 (SOCS3) gene in liver tissue is associated with a poorer treatment outcome in patients with chronic hepatitis C viral genotype 1. Also, insulin resistance has been implicated in nonresponse to an anti-HCV treatment. To understand why HCV genotype 1 patients respond differently, we investigated SOCS3 gene expression, metabolic syndrome (MS), and the response to therapy in a cohort of patients with HCV-related hepatitis. A total of 198 patients (108 with genotype 1 and 90 with genotype 2) treated with pegylated interferon plus ribavirin were consecutively enrolled in the study. We measured SOCS3 expression in Epstein-Barr virus-transformed lymphoblastoid cell lines derived from peripheral lymphocytes of a subset of 130 patients. MS was more frequent in genotype 1 patients than in genotype 2 patients (P < 0.01). Nonresponders (P < 0.01), MS (P < 0.001), and genotype 1 (P < 0.001) were significantly related to SOCS3 overexpression. However, SOCS3 levels were higher in nonresponders also, regardless of the genotype (P < 0.01). In a univariate analysis, the genotype (P < 0.001), age (P < 0.001), SOCS3 (P < 0.001), and MS (P < 0.001) were significantly related to the response to therapy. However, in a multivariate analysis, SOCS3 was the only independent predictor of the response (odds ratio = 6.7; P < 0.005). CONCLUSION: We speculate that SOCS3 expression per se may influence the response to antiviral therapy and that the genotype 1b virus might induce its up-regulation. This may account for the different responses to therapy between genotype 1-infected and genotype 2-infected patients.


Subject(s)
Antiviral Agents/therapeutic use , Hepatitis C, Chronic/drug therapy , Hepatitis C, Chronic/metabolism , Insulin Resistance/physiology , Interferon-alpha/therapeutic use , Polyethylene Glycols/therapeutic use , Ribavirin/therapeutic use , Suppressor of Cytokine Signaling Proteins/metabolism , Adult , Aged , Biopsy , Cell Line , Cohort Studies , Drug Therapy, Combination , Female , Genotype , Hepacivirus/genetics , Hepatitis C, Chronic/genetics , Humans , Insulin Resistance/genetics , Interferon alpha-2 , Liver/metabolism , Liver/pathology , Liver/virology , Male , Metabolic Syndrome/genetics , Metabolic Syndrome/metabolism , Middle Aged , Recombinant Proteins , Suppressor of Cytokine Signaling 3 Protein , Suppressor of Cytokine Signaling Proteins/genetics , Treatment Outcome
15.
Curr Diabetes Rev ; 3(1): 15-23, 2007 Feb.
Article in English | MEDLINE | ID: mdl-18220652

ABSTRACT

Glucagon-like peptide-1 (GLP-1) may contribute to the decreased incretin effect characterizing type 2 diabetes. Multiple actions other than insulin secretion stimulation give to GLP-1 a highly desirable profile for an antidiabetic agent. To overcome the need for continuous infusion of the native compound, which is rapidly degraded by dimethyl-peptidyl-peptidase-IV (DPP-IV), analogues with low affinity for this protease have been developed. A second major strategy is represented by DPP-IV inhibitors that act to increase endogenous GLP-1. On the basis of the promising results in clinical trials, the incretin-based therapy may offer an useful option for diabetes management.


Subject(s)
Diabetes Mellitus, Type 2/drug therapy , Glucagon-Like Peptide 1/therapeutic use , Dipeptidyl Peptidase 4 , Dipeptidyl-Peptidase IV Inhibitors , Drug Delivery Systems , Enzyme Inhibitors/therapeutic use , Gastric Inhibitory Polypeptide/physiology , Glucagon-Like Peptide 1/analogs & derivatives , Glucagon-Like Peptide 1/metabolism , Glucagon-Like Peptide 1/physiology , Humans , Hypoglycemic Agents/therapeutic use , Incretins/pharmacology , Liraglutide , Maleimides/therapeutic use , Peptides/therapeutic use , Protein Processing, Post-Translational , Signal Transduction/drug effects
16.
J Hypertens ; 24(8): 1655-61, 2006 Aug.
Article in English | MEDLINE | ID: mdl-16877970

ABSTRACT

OBJECTIVES: Advanced diabetic nephropathy (DN) is characterized by a marked development of cardiovascular and renal disease. These patients are frequently managed by different health professionals with the consequence that the quality of care may differ substantially. To compare the management of cardiovascular risk factors in patients with type 2 DN and an estimated glomerular filtration rate (GFR) of 15-60 ml/min per 1.73 m2 followed in nephrology, diabetology and primary care. METHODS: This multicentre cross-sectional study verified the control of blood pressure (BP), total cholesterol, triglycerides, glycosylated haemoglobin A1c (HbA1c) and haemoglobin in patients exclusively followed in either nephrology (n = 266), diabetology (n = 246) or primary care (n = 195) of the same metropolitan area for at least 1 year. RESULTS: Primary care patients were older and had a greater prevalence of previous cardiovascular events. The GFR was lower in nephrology than in diabetology and primary care (33 +/- 13 versus 47 +/- 9 and 40 +/- 12 ml/min per 1.73 m2, P < 0.0001). The prevalence of BP target (< 130/80 mmHg) was similarly low in nephrology, diabetology and primary care (14, 13 and 10%, P = 0.421) probably because of insufficient prescription of diuretics and low-salt diet. Whereas the prevalence of the triglycerides target was similar, that of total cholesterol (< 200 mg/dl) was larger in diabetology (63%) than in nephrology and primary care (59 and 46%, P = 0.003) because of greater statin prescription in hypercholesterolemic individuals (70, 50 and 41%, respectively, P = 0.002). The attainment of HbA1c less than 7% was less frequent in diabetology (32%) than in nephrology and primary care (61 and 46%, P = 0.0003) despite a more frequent prescription of insulin/oral agents in diabetology. The control of anaemia was better in diabetology. Multivariate analysis adjusted for the patient case-mix and physician-level clustering confirmed these differences except for anaemia. CONCLUSION: Patients with advanced DN, despite the worst renal and cardiovascular prognosis, are at high risk of being under-treated independently of the type of clinical setting.


Subject(s)
Cardiovascular Diseases/epidemiology , Diabetes Mellitus, Type 2/epidemiology , Diabetic Nephropathies/epidemiology , Nephrology , Primary Health Care , Adult , Aged , Aged, 80 and over , Analysis of Variance , Anemia/drug therapy , Anemia/epidemiology , Anemia/physiopathology , Anticholesteremic Agents/therapeutic use , Antihypertensive Agents/therapeutic use , Biomarkers/blood , Blood Pressure , Cardiovascular Diseases/drug therapy , Cardiovascular Diseases/physiopathology , Cholesterol, LDL/blood , Confounding Factors, Epidemiologic , Cross-Sectional Studies , Diabetes Mellitus, Type 2/drug therapy , Diabetes Mellitus, Type 2/physiopathology , Diabetic Nephropathies/drug therapy , Diabetic Nephropathies/physiopathology , Dyslipidemias/drug therapy , Dyslipidemias/epidemiology , Dyslipidemias/physiopathology , Female , Glomerular Filtration Rate , Glycated Hemoglobin/metabolism , Humans , Hypoglycemic Agents/therapeutic use , Italy/epidemiology , Male , Middle Aged , Prevalence , Risk Factors , Treatment Outcome , Triglycerides/blood
17.
Diabetes Care ; 29(3): 498-503, 2006 Mar.
Article in English | MEDLINE | ID: mdl-16505495

ABSTRACT

OBJECTIVE: The purpose of this study was to assess the prevalence of cardiorenal risk factors, their management in a routine clinical setting, and the actual achievement of international guideline targets in a large cohort of type 2 diabetic patients with diabetic nephropathy. RESEARCH DESIGN AND METHODS: A multicentric cross-sectional study was performed in the Campania region in Italy to evaluate cardiorenal risk factors and their management in light of international guidelines. Overall, 28,550 diabetic patients were screened in the 21 participating centers; 847 (348 male and 449 female) patients with type 2 diabetes and a clinical diagnosis of diabetic nephropathy were recruited. RESULTS: Of these subjects, 749 had microalbuminuria and 98 had macroalbuminuria. Targets for blood pressure, HbA(1c), LDL cholesterol, HDL cholesterol, and triglycerides were reached in, respectively, 17.5, 32.3, 30.7, 47, and 55.2% of the patients. Chronic renal failure (glomerular filtration rate <60 ml/min) was revealed in 41% and anemia in 23.8% of the patients. CONCLUSIONS: This is the first study to investigate a large cohort of type 2 diabetic patients with early and moderate diabetic nephropathy strictu sensu. Notably, impaired renal function can be often diagnosed in these patients even in the presence of microalbuminuria. Thus, clinical diagnosis of diabetic nephopathy allows us to identify a group of patients at very high cardiorenal risk, for whom care is really difficult. We suggest that a correct diagnosis of diabetic nephropathy should always be made and that sodium intake and anemia should be routinely evaluated in these patients.


Subject(s)
Cardiovascular Diseases/etiology , Diabetes Mellitus, Type 2/complications , Diabetic Nephropathies/complications , Adult , Aged , Albuminuria/physiopathology , Cardiovascular Diseases/epidemiology , Cross-Sectional Studies , Diabetes Mellitus, Type 2/rehabilitation , Diabetes Mellitus, Type 2/therapy , Diabetic Nephropathies/therapy , Female , Humans , Hypertension/therapy , Italy/epidemiology , Male , Middle Aged , Prevalence , Risk Factors
18.
Monaldi Arch Chest Dis ; 64(1): 63-6, 2005 Mar.
Article in Italian | MEDLINE | ID: mdl-16128169

ABSTRACT

Incidental detection of a mediastinal mass in a asymptomatic patient poses a not easy diagnostic problem. For solid masses or cysts, histology or cytology is often necessary. Although substernal extension of a cervical goiter is common, totally intrathoracic primary thyroidal mass is unusual. We describe a rare case of heterotopic accessory mediastinal thyroid in a patient completely asymptomatic both for signs of thyroid dysfunction and mechanical compression. Radiological and hormonal 6 and 12 months follow-up is reported.


Subject(s)
Choristoma/diagnosis , Mediastinal Diseases/diagnosis , Thyroid Gland , Adult , Choristoma/diagnostic imaging , Humans , Male , Mediastinal Diseases/diagnostic imaging , Radiography , Radionuclide Imaging , Thyroid Function Tests
19.
J Am Coll Cardiol ; 46(5): 827-34, 2005 Sep 06.
Article in English | MEDLINE | ID: mdl-16139132

ABSTRACT

OBJECTIVES: The aim of the present study was to evaluate the expression and the activity of vascular endothelial growth factor (VEGF) in the hearts of diabetic patients with chronic coronary heart disease (CHD). BACKGROUND: Diabetes is characterized by a decreased collateral vessel formation in response to coronary ischemic events, although the role of VEGF in human diabetic macroangiopathy has not been fully investigated. METHODS: Biopsies of left ventricular (LV) myocardium were obtained from 10 patients with type 2 diabetes and 10 non-diabetic patients with chronic CHD, all undergoing surgical coronary revascularization. Right ventricle myocardial samples taken from normal hearts were used as control specimens. Vascular endothelial growth factor and VEGF-receptors (flt-1 and flk-1) were evaluated by Western blot, reverse transcriptase-polymerase chain reaction (RT-PCR) and real-time RT-PCR. Akt and endothelial nitric oxide synthase (eNOS) protein expression and their phosphorylated forms were also evaluated by Western blot. RESULTS: Vascular endothelial growth factor, flt-1, and flk-1 messenger ribonucleic acid (mRNA) and protein expressions were increased in non-diabetic patients with CHD compared with control subjects. Remarkably, in diabetic patients, VEGF mRNA and protein levels were significantly higher, whereas flt-1, flk-1 mRNA, and protein were lower when compared with non-diabetic patients. Interestingly, phospho-flk-1 was reduced in diabetic patients compared with non-diabetic patients. As a consequence, Akt phosphorylation, eNOS protein and its phosphorylated form were significantly higher in the samples from non-diabetic patients compared with diabetic patients. CONCLUSIONS: Chronic CHD in diabetic patients is characterized by an increased VEGF myocardial expression and a decreased expression of its receptors along with a down-regulation of its signal transduction. The latter could be partially responsible for the reduced neoangiogenesis in diabetic patients with ischemic cardiomyopathy.


Subject(s)
Coronary Artery Disease/physiopathology , Diabetes Mellitus, Type 2/physiopathology , Myocardium , Receptors, Vascular Endothelial Growth Factor/physiology , Vascular Endothelial Growth Factors/biosynthesis , Aged , Case-Control Studies , Chronic Disease , Coronary Artery Disease/metabolism , Diabetes Mellitus, Type 2/metabolism , Diabetic Angiopathies , Endothelium, Vascular/physiopathology , Humans , Male , Middle Aged , Signal Transduction , Vascular Endothelial Growth Factors/physiology
20.
J Clin Endocrinol Metab ; 90(9): 5167-74, 2005 Sep.
Article in English | MEDLINE | ID: mdl-15956086

ABSTRACT

CONTEXT: The opioid system is involved in blood pressure regulation in both normal humans and patients with essential hypertension. OBJECTIVE: The objective of the study was to investigate the effects of a high-dose infusion of beta-endorphin, an opioid peptide, on blood pressure and on the hormonal profile in healthy subjects and in hypertensive patients and the mediation played by opioid receptor agonism. DESIGN, SETTING, AND PARTICIPANTS: According to a randomized double-blind design, 11 healthy subjects (controls) and 12 hypertensive inpatients (mean age, 38.9 and 40.4 yr, respectively) received 1-h iv infusion of beta-endorphin (250 mug/h) and, on another occasion, the same infusion protocol preceded by the opioid antagonist naloxone (8 mg). MAIN OUTCOME MEASURES: Hemodynamic and hormonal measurements were performed at established times during the infusion protocols. RESULTS: At baseline, circulating beta-endorphin, norepinephrine, and endothelin-1 in hypertensive patients were significantly (P < 0.05) higher than in controls. In controls, beta-endorphin reduced blood pressure (P < 0.01) and circulating norepinephrine (P < 0.02) and increased plasma atrial natriuretic factor (P < 0.003) and GH (P < 0.0001). In hypertensive patients, beta-endorphin decreased systemic vascular resistance (P < 0.0001), blood pressure (P < 0.0001), and plasma norepinephrine (P < 0.0001) and endothelin-1 (P < 0.0001) and raised circulating atrial natriuretic factor (P < 0.0001), GH (P < 0.0001), and IGF-I (P < 0.0001). These hemodynamic and hormonal responses to beta-endorphin in hypertensive patients were significantly (P < 0.0001) greater than in controls but were annulled in all individuals when naloxone preceded beta-endorphin infusion. CONCLUSIONS: High doses of beta-endorphin induce hypotensive and beneficial hormonal effects in humans, which are enhanced in essential hypertension and are mediated by opioid receptors.


Subject(s)
Blood Pressure/drug effects , Hormones/blood , Hypertension/drug therapy , Hypertension/physiopathology , Receptors, Opioid/agonists , beta-Endorphin/administration & dosage , Adult , Dose-Response Relationship, Drug , Double-Blind Method , Female , Hemodynamics/drug effects , Humans , Hypertension/blood , Male , Middle Aged , Naloxone/pharmacology , Narcotic Antagonists/pharmacology , beta-Endorphin/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...